scholarly journals Action on diabetic macular oedema: achieving optimal patient management in treating visual impairment due to diabetic eye disease

Eye ◽  
2017 ◽  
Vol 31 (S1) ◽  
pp. S1-S20 ◽  
Author(s):  
R Gale ◽  
P H Scanlon ◽  
M Evans ◽  
F Ghanchi ◽  
Y Yang ◽  
...  
Keyword(s):  
Visual Impairment ◽  
Macular Oedema ◽  
Patient Management ◽  
Diabetic Macular Oedema ◽  
Eye Disease ◽  
Diabetic Eye Disease ◽  
Optimal Patient Management

scholarly journals Cost-effectiveness of ranibizumab in treatment of diabetic macular oedema (DME) causing visual impairment: evidence from the RESTORE trial

2012 ◽  
Vol 96 (5) ◽  
pp. 688-693 ◽  
Author(s):  
Paul Mitchell ◽  
Lieven Annemans ◽  
Meghan Gallagher ◽  
Rafiq Hasan ◽  
Simu Thomas ◽  
...  
Keyword(s):  
Cost Effectiveness ◽  
Visual Impairment ◽  
Macular Oedema ◽  
Diabetic Macular Oedema

One-year real-life results on effect of intravitreal aflibercept in patients with diabetic macular oedema switched from ranibizumab

2020 ◽  
pp. 112067212092727
Author(s):  
Marko Lukic ◽  
Gwyn Williams ◽  
Zaid Shalchi ◽  
Praveen J Patel ◽  
Philip G Hykin ◽  
...  
Keyword(s):  
Visual Acuity ◽  
Diabetic Retinopathy ◽  
Early Treatment ◽  
Macular Oedema ◽  
Real Life ◽  
Diabetic Macular Oedema ◽  
Foveal Thickness ◽  
Macular Volume ◽  
Central Foveal Thickness ◽  
The Mean

Purpose To assess visual and optical coherence tomography–derived anatomical outcomes of treatment with intravitreal aflibercept (Eylea®) for diabetic macular oedema in patients switched from intravitreal ranibizumab (Lucentis®). Design Retrospective, cohort study. Participants Ninety eyes (of 67 patients) receiving intravitreal anti–vascular endothelial growth factor therapy were included. Methods This is a retrospective, real-life, cohort study. Each patient had visual acuity measurements and optical coherence tomography scans performed at baseline and 12 months after the first injection of aflibercept was given. Main Outcome Measures We measured visual acuities in Early Treatment Diabetic Retinopathy Study letters, central foveal thickness and macular volume at baseline and at 12 months after the first aflibercept injection was given. Results Ninety switched eyes were included in this study. The mean (standard deviation) visual acuity was 63 (15.78) Early Treatment Diabetic Retinopathy Study letters. At baseline, the mean (standard deviation) central foveal thickness was 417.7 (158.4) μm and the mean macular volume was 9.96 (2.44) mm3. Mean change in visual acuity was +4 Early Treatment Diabetic Retinopathy Study letters (p = 0.0053). The mean change in macular volume was −1.53 mm 3 in SW group (p = 0.21), while the change in central foveal thickness was −136.8 μm (p = 0.69). Conclusion There was a significant improvement in visual acuity and in anatomical outcomes in the switched group at 12 months after commencing treatment with aflibercept for diabetic macular oedema.

Sign in / Sign up

Export Citation Format

Share Document